Ascendis Pharma A/S (ASND) Analysts See $-1.18 EPS; Autoweb (AUTO) Shorts Up By 4.57%

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-1.18 EPS on March, 27.They anticipate $0.10 EPS change or 9.26% from last quarter’s $-1.08 EPS. After having $-0.94 EPS previously, Ascendis Pharma A/S’s analysts see 25.53% EPS growth. The stock increased 2.86% or $3.62 during the last trading session, reaching $129.99. About 452,217 shares traded or 21.25% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 89.47% since March 14, 2018 and is uptrending. It has outperformed by 85.10% the S&P500. Some Historical ASND News: 29/03/2018 – ASCENDIS PHARMA A/S ASND.O : LEERINK RAISES TARGET PRICE TO $64 FROM $37; 23/04/2018 – NODELMAN SAYS ASCENDIS PHARMA WORTH $289/SHARE AT SOHN CONF; 28/03/2018 – ASCENDIS PHARMA A/S – AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF EUR 195.4 MLN COMPARED TO EUR 180.3 MLN AS OF DEC 31, 2016; 30/05/2018 – ASCENDIS PHARMA A/S – CONTINUED EXECUTION AND ACHIEVEMENT OF PLANNED MILESTONES ACROSS 3 WHOLLY-OWNED CLINICAL PROGRAMS IN RARE ENDOCRINE DISEASES; 07/05/2018 – Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology; 28/03/2018 – ASCENDIS PHARMA A/S – RARE DISEASE ENDOCRINOLOGY PIPELINE ADVANCES, WITH SIGNIFICANT MILESTONES ANTICIPATED OVER NEXT TWELVE MONTHS; 20/03/2018 – ASCENDIS PHARMA A/S ASND.O : CREDIT SUISSE RAISES TARGET PRICE TO $78 FROM $50; RATING OUTPERFORM; 28/03/2018 – Ascendis Pharma A/S Reports Full Year 2017 Financial Results; 08/05/2018 – Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP; 02/04/2018 – Fidelity Select Pharmaceuticals Adds Ascendis Pharma A/S

Autoweb Inc (NASDAQ:AUTO) had an increase of 4.57% in short interest. AUTO’s SI was 656,700 shares in March as released by FINRA. Its up 4.57% from 628,000 shares previously. With 27,800 avg volume, 24 days are for Autoweb Inc (NASDAQ:AUTO)’s short sellers to cover AUTO’s short positions. The SI to Autoweb Inc’s float is 8.67%. The stock increased 7.42% or $0.33 during the last trading session, reaching $4.78. About 198,708 shares traded or 305.29% up from the average. AutoWeb, Inc. (NASDAQ:AUTO) has declined 49.64% since March 14, 2018 and is downtrending. It has underperformed by 54.01% the S&P500. Some Historical AUTO News: 16/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of AutoWeb, Inc. Investors (AUTO); 08/03/2018 – AUTOWEB INC – WESLEY OZIMA WILL BE NAMED INTERIM CFO; 15/03/2018 – PITON CAPITAL PARTNERS LLC REPORTS 5.3 PCT PASSIVE STAKE IN AUTOWEB INC AS OF MARCH 12, 2018 – SEC FILING; 08/03/2018 – AUTOWEB INC – KIMBERLY BOREN WILL BE STEPPING DOWN AS CFO; 12/04/2018 – AutoWeb Appoints Industry Veteran Jared Rowe to President and Chief Executive Officer; 28/03/2018 – AUTOWEB – ON MARCH 22, CO WAS TERMINATING LOAN AGREEMENT WITH UNION BANK, WHICH WAS INITIALLY ENTERED INTO ON FEBRUARY 26, 2013; 08/03/2018 – AUTOWEB INC – CEO JEFF COATS TO STEP DOWN; 08/03/2018 – AUTOWEB – CO WAS UNABLE TO FULLY MEET DEMAND FOR LEADS AND CLICKS IN QTR DUE TO HIGHER TRAFFIC ACQUISITION COSTS; 08/03/2018 AutoWeb Announces Executive Management Succession Process; 12/04/2018 – AUTOWEB INC – ROWE SUCCEEDING JEFFREY COATS

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: which released: “Health Care Sector Update for 03/13/2019: ACB,GH,ASND – Nasdaq” on March 13, 2019, also with their article: “Health Care Sector Update for 03/13/2019: AMRX,ACB,ACB.TO,GH,ASND – Nasdaq” published on March 13, 2019, published: “Ascendis Pharma prices equity offering at $120 – Seeking Alpha” on March 06, 2019. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: and their article: “Ascendis Pharma: Positioned To Target Growth Hormone Deficiency In Children – Seeking Alpha” published on February 26, 2019 as well as‘s news article titled: “European ADRs Move Higher in Wednesday Trading – Nasdaq” with publication date: March 13, 2019.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $6.02 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Among 5 analysts covering Ascendis Pharma (NASDAQ:ASND), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma had 6 analyst reports since January 24, 2019 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, March 4. J.P. Morgan maintained the stock with “Buy” rating in Thursday, March 7 report. The firm has “Buy” rating by Wedbush given on Thursday, March 7. Canaccord Genuity maintained it with “Buy” rating and $132 target in Monday, March 4 report. As per Thursday, January 24, the company rating was upgraded by Leerink Swann.

More notable recent AutoWeb, Inc. (NASDAQ:AUTO) news were published by: which released: “Texas Instruments New Converter to Aid Auto & Industrial Space – Nasdaq” on March 13, 2019, also with their article: “Copart Expands in Kentucky With Vincent Auto Acquisition – Nasdaq” published on March 11, 2019, published: “Brazil auto output jumps nearly 30 pct in February, sales flat – Nasdaq” on March 11, 2019. More interesting news about AutoWeb, Inc. (NASDAQ:AUTO) were released by: and their article: “VW CEO expects software to make up 90 pct of auto industry innovation – Nasdaq” published on March 12, 2019 as well as‘s news article titled: “China auto sales fall 14 pct in February, mark eighth month of decline – Nasdaq” with publication date: March 11, 2019.

AutoWeb, Inc. operates as an automotive marketing services firm in the United States. The company has market cap of $62.07 million. It assists automotive retail dealers and manufacturers to market and sell new and used vehicles to clients through its programs. It currently has negative earnings. The companyÂ’s products include new vehicle lead program, which allows clients to submit requests for pricing and availability of specific makes and models; and used vehicle lead program, as well as finance leads program, which provides vehicle financing and other services from dealers or financial institutions.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart